Nina E. Gakii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nina E. Gakii has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Bradley K. Taylor
Department of Anesthesiology and Perioperative Medicine, Department of Pharmacology, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
3 shared publications - Paramita Basu
Department of Anesthesiology and Perioperative Medicine, Department of Pharmacology, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
2 shared publications Adam Brandner
Department of Anesthesiology and Perioperative Medicine, Center for Neuroscience, Pittsburgh Center for Pain Research, Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
1 shared publication- Albert T. M. Yeung
Department of Biology, University of Pennsylvania, Philadelphia, PA, United States
1 shared publication - David Hilferty
University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA
1 shared publication - Diogo F. S. Santos
Department of Anesthesiology and Perioperative Medicine, Department of Pharmacology, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
1 shared publication
Latest Publications
- Open Access
- 18 August 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (9) , 2117-2127
Parabrachial neuropeptide Y Y1 receptor–expressing neurons govern the sensory dimension of neuropathic pain
Pain perception involves complex sensory and emotional processes, yet the supraspinal circuits that sustain neuropathic pain remain incompletely understood. Here, we demonstrate that parabrachial nucleus (PBN) neurons expressing the inhibitory G-protein–coupled neuropeptide Y Y1 receptor ( Npy1r ) are critical modulators of neuropathic pain. Approximately 19% of lateral PBN neurons express Npy1r. Stimulus-evoked Fos activation and calcium dynamics of these neurons increases in mice with spared nerve injury (SNI) compared to sham controls. Pharmacological activation of Y1 receptors or chemogenetic inhibition of Npy1r neurons attenuates SNI-induced mechanical and cold allodynia, without altering baseline sensitivity or conditioned place preference (a measure of affective pain). Preemptive ablation of parabrachial Npy1r neurons before SNI delayed the development of neuropathic hypersensitivity. Conversely, repeated chemogenetic activation of Npy1r neurons produced persistent mechanical and cold hypersensitivity in uninjured animals; this outlasted neuronal activation, indicating sufficiency to drive pain-like states. Viral tracing revealed dense Npy1r projections from lateral parabrachial neurons to forebrain regions including the central amygdala, lateral hypothalamus, zona incerta, and ventromedial thalamus, sites implicated in the sensory and affective dimension of pain. These findings demonstrate that Npy1r -expressing PBN neurons selectively regulate the sensory-discriminative component of neuropathic pain and can maintain long-lasting hypersensitivity even in the absence of injury.
- 18 August 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (9) , 2117-2127
Open AccessParabrachial neuropeptide Y Y1 receptor–expressing neurons govern the sensory dimension of neuropathic pain
Pain perception involves complex sensory and emotional processes, yet the supraspinal circuits that sustain neuropathic pain remain incompletely understood. Here, we demonstrate that parabrachial nucleus (PBN) neurons expressing the inhibitory G-protein–coupled neuropeptide Y Y1 receptor ( Npy1r ) are critical modulators of neuropathic pain. Approximately 19% of lateral PBN neurons express Npy1r. Stimulus-evoked Fos activation and calcium dynamics of these neurons increases in mice with spared nerve injury (SNI) compared to sham controls. Pharmacological activation of Y1 receptors or chemogenetic inhibition of Npy1r neurons attenuates SNI-induced mechanical and cold allodynia, without altering baseline sensitivity or conditioned place preference (a measure of affective pain). Preemptive ablation of parabrachial Npy1r neurons before SNI delayed the development of neuropathic hypersensitivity. Conversely, repeated chemogenetic activation of Npy1r neurons produced persistent mechanical and cold hypersensitivity in uninjured animals; this outlasted neuronal activation, indicating sufficiency to drive pain-like states. Viral tracing revealed dense Npy1r projections from lateral parabrachial neurons to forebrain regions including the central amygdala, lateral hypothalamus, zona incerta, and ventromedial thalamus, sites implicated in the sensory and affective dimension of pain. These findings demonstrate that Npy1r -expressing PBN neurons selectively regulate the sensory-discriminative component of neuropathic pain and can maintain long-lasting hypersensitivity even in the absence of injury.
- Open Access
- 11 January 2026
- Published by Elsevier in Brain Research
- Vol. 1875, 150162
EAE models of neuropathic pain in multiple sclerosis do not require pertussis toxin
- 11 January 2026
- Published by Elsevier in Brain Research
- Vol. 1875, 150162
Open AccessEAE models of neuropathic pain in multiple sclerosis do not require pertussis toxin
- Open Access
- 12 August 2025
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 10 (5) , e1312
Long-lasting and fast methylglyoxal-scavenging peptide CycK(Myr)R4E alleviates chronic pain in type 2 diabetic mice
Introduction: Pathological levels of methylglyoxal (MG), a reactive dicarbonyl product of glucose, contribute to major neurological complications associated with type II diabetes, including chronic neuropathic pain. Strategies to target elevated MG have included small molecule MG scavengers, but scavenger deficiencies in proteolytic stability and onset of scavenging activity have precluded clinical translation. To address this gap, we developed a long-lasting and highly reactive cyclic peptide CycK(Myr)R4E, and here evaluated its antihyperalgesic efficacy in the db/db mouse model of type II diabetes painful diabetic neuropathy. Objectives: To test the hypothesis that CycK(Myr)R4E can reduce behavioral and molecular signs of painful diabetic neuropathy. Methods: We assessed heat hypersensitivity as an index of hyperalgesia, and touch-evoked expression of phosphorylated extracellular signal–regulated kinase as a measure of neuronal activity in spinal cord dorsal horn. Results: We report that a single systemic injection of CycK(Myr)R4E (3 mg/kg) reversed heat hypersensitivity. Repeated systemic injection of CycK(Myr)R4E (0.125 mg/kg, 3 times per week, 6–12 weeks of age) prevented heat hypersensitivity and reduced stimulus-evoked phosphorylated extracellular signal–regulated kinase. Conclusion: These studies promote CycK(Myr)R4E as the most promising MG scavenger for the prevention and treatment of hyperalgesia in type 2 diabetic neuropathic pain.
- 12 August 2025
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 10 (5) , e1312
Open AccessLong-lasting and fast methylglyoxal-scavenging peptide CycK(Myr)R4E alleviates chronic pain in type 2 diabetic mice
Introduction: Pathological levels of methylglyoxal (MG), a reactive dicarbonyl product of glucose, contribute to major neurological complications associated with type II diabetes, including chronic neuropathic pain. Strategies to target elevated MG have included small molecule MG scavengers, but scavenger deficiencies in proteolytic stability and onset of scavenging activity have precluded clinical translation. To address this gap, we developed a long-lasting and highly reactive cyclic peptide CycK(Myr)R4E, and here evaluated its antihyperalgesic efficacy in the db/db mouse model of type II diabetes painful diabetic neuropathy. Objectives: To test the hypothesis that CycK(Myr)R4E can reduce behavioral and molecular signs of painful diabetic neuropathy. Methods: We assessed heat hypersensitivity as an index of hyperalgesia, and touch-evoked expression of phosphorylated extracellular signal–regulated kinase as a measure of neuronal activity in spinal cord dorsal horn. Results: We report that a single systemic injection of CycK(Myr)R4E (3 mg/kg) reversed heat hypersensitivity. Repeated systemic injection of CycK(Myr)R4E (0.125 mg/kg, 3 times per week, 6–12 weeks of age) prevented heat hypersensitivity and reduced stimulus-evoked phosphorylated extracellular signal–regulated kinase. Conclusion: These studies promote CycK(Myr)R4E as the most promising MG scavenger for the prevention and treatment of hyperalgesia in type 2 diabetic neuropathic pain.